Lipocine Inc (New) (LPCN)
Lipocine is clinical-stage biopharmaceutical company focused on applying its oral drug delivery technology for the development of pharmaceutical products focusing on neuroendocrine and metabolic disorders. Co. has a license agreement for the development and commercialization its product candidate, TLANDO®, an oral testosterone replacement therapy comprised of testosterone undecanoate. Co.'s additional pipeline candidates, LPCN 1148 comprising a prodrug of testosterone, testosterone laurate, for the management of decompensated cirrhosis. Co. is conducting a Phase 2 POC study in male cirrhotic subjects to evaluate the therapeutic potential of LPCN 1148 for the management of sarcopenia.
| Company Name: |
Lipocine Inc (New) |
| Website: |
www.lipocine.com |
| Sector: |
Drugs & Pharmaceuticals |
| Number of ETFs Holding LPCN: |
2 |
| Total Market Value Held by ETFs: |
$1.01M |
| Total Market Capitalization: |
$28.00M |
| % of Market Cap. Held by ETFs: |
3.61% |
|
|
April 18, 2024 • 3:46 AM Eastern
Strong Buy (4.00 out of 4)
100th percentile
|
|
Free LPCN Email Alerts:
